Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.

Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL

Hum Pathol, (9):974-979 1992

MED: 1355464

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.

Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L

J Clin Oncol, (4):599-605 1992

MED: 1548522

Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.

Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M

Cell, (4):549-554 1988

MED: 2453289

Title not supplied

Alper

Cell Growth and Differentiation. 1990

Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P

Cancer Res, (13):4087-4091 1990

MED: 1972347

Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease.

Berchuck A, Rodriguez G, Kinney RB, Soper JT, Dodge RK, Clarke-Pearson DL, Bast RC Jr

Am J Obstet Gynecol, (1 Pt 1):15-21 1991

MED: 1670908

Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector.

Bernards R, Destree A, McKenzie S, Gordon E, Weinberg RA, Panicali D

Proc Natl Acad Sci U S A, (19):6854-6858 1987

MED: 3477812

Using a neural network to identify potential HLA-DR1 binding sites within proteins.

Bisset LR, Fierz W

J Mol Recognit, (1):41-48 1993

MED: 8251191

ras oncogenes in human cancer: a review.

Bos JL

Cancer Res, (17):4682-4689 1989

MED: 2547513

Prevalence of ras gene mutations in human colorectal cancers.

Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, Vogelstein B

Nature, (6120):293-297 1987

MED: 3587348